Holen Sie sich die Stockscreener-App
5.02
0.60%
0.03
Schlusskurs vom Vortag:
$4.99
Offen:
$5.08
24-Stunden-Volumen:
11,345
Relative Volume:
0.41
Marktkapitalisierung:
$772.51M
Einnahmen:
$117.10K
Nettoeinkommen (Verlust:
$-161.61M
KGV:
-2.0865
EPS:
-2.4059
Netto-Cashflow:
-
1W Leistung:
-3.65%
1M Leistung:
+13.83%
6M Leistung:
+76.14%
1J Leistung:
+51.43%
1-Tages-Spanne:
$5.005
$5.2636
1-Wochen-Bereich:
$4.77
$5.3543
52-Wochen-Spanne:
$1.79
$6.30
Opthea Limited Adr Stock (OPT) Company Profile
Firmenname
Opthea Limited Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie OPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OPT
Opthea Limited Adr
|
5.02 | 772.51M | 117.10K | -161.61M | 0 | -2.4059 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Opthea Limited Adr Stock (OPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-26 | Eingeleitet | SVB Leerink | Outperform |
| 2020-11-17 | Eingeleitet | Citigroup | Buy |
| 2020-11-11 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-11 | Eingeleitet | SVB Leerink | Outperform |
| 2020-11-11 | Eingeleitet | Truist | Buy |
Alle ansehen
Opthea Limited Adr Aktie (OPT) Neueste Nachrichten
Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position - TipRanks
Opthea Completes Key Phase 3 Trial Milestone in Wet AMD Treatment - TipRanks
Opthea to Present at Oppenheimer Healthcare Conference - GlobeNewswire Inc.
OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Is Opthea Limited (OPT) One of the Best ASX Stocks to Buy According to Hedge Funds? - Insider Monkey
Opthea Unveils Promising Wet AMD Therapy at Investor Day - TipRanks
Jane Street Group LLC Invests $114,000 in Opthea Limited (NASDAQ:OPT) - Defense World
Opthea’s Innovative Approach to AMD Treatment with Sozinibercept - TipRanks
Opthea to Host Investor Days in New York and Australia - The Manila Times
Opthea Sets Key 2025 Investor Events to Showcase Breakthrough Wet AMD Treatment Sozinibercept - StockTitan
EX-99.1 - SEC.gov
Opthea to Present Phase 3 Trial Update at J.P. Morgan Healthcare Conference - TipRanks
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Opthea to Present Phase 3 AMD Trial Data at JP Morgan Healthcare Conference - StockTitan
Opthea's Wet AMD Program to be Featured at FLORetina 2024 - The Manila Times
Opthea’s Wet AMD Program to be Featured at FLORetina 2024 - Yahoo Finance
Opthea Highlights Innovative Wet AMD Therapy - TipRanks
Opthea to Participate in Citi 2024 Global Healthcare Conference - Yahoo Finance
Opthea Limited to Engage Investors at Healthcare Conference - TipRanks
Opthea CEO to Present at Citi Healthcare Conference, Spotlights Eye Disease Treatment - StockTitan
Opthea Limited Targets AMD Market with Sozinibercept - TipRanks
Opthea Appoints Kathy Connell to Board of Directors - The Manila Times
Opthea : Chairman’s Address to the 2024 Annual General Meeting Form 6 K - Marketscreener.com
Opthea Limited Announces Board Changes - Marketscreener.com
Opthea's Sozinibercept Shows Superior Results in Phase 2b Eye Disease Trial - StockTitan
Opthea's Wet AMD Program Featured at Ophthalmology Events - The Manila Times
Opthea (NASDAQ:OPT) Shares Up 1.7% – What’s Next? - Defense World
Opthea to Participate in November Investor Conferences - The Manila Times
Opthea : UPDATE Opthea to Participate in November Investor Conferences Form 6 K - Marketscreener.com
Opthea Limited Strengthens Leadership and Advances AMD Treatment - TipRanks
FY2025 EPS Estimates for Opthea Lifted by Leerink Partnrs - Defense World
Is Opthea Limited (OPT) the Penny Stock with the Biggest Upside Potential According to Analysts? - Insider Monkey
Opthea Files Notice of Annual General Meeting - The Manila Times
Opthea Ltd stock soars to 52-week high, touches $4.95 - Investing.com India
Opthea Ltd stock soars to 52-week high, touches $4.95 By Investing.com - Investing.com South Africa
Opthea Wet AMD Program to be Presented at Innovate Retina - The Manila Times
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025 - The Manila Times
Opthea Limited Announces Chief Financial Officer Changes - Marketscreener.com
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 - The Manila Times
Opthea Advances Retinal Disease Treatments - TipRanks
Opthea Advances nAMD Treatment with Sozinibercept - TipRanks
Opthea Joins the S&P/ASX 300 Index - StockTitan
Opthea Limited (NASDAQ:OPT) Shares Sold by Victory Capital Management Inc. - Defense World
Opthea Advances Toward Sozinibercept Commercialization - TipRanks
Opthea’s Sozinibercept Eyes Breakthrough in AMD Therapy - TipRanks
FY2025 EPS Estimates for Opthea Limited Boosted by HC Wainwright (NASDAQ:OPT) - Defense World
Research Analysts Set Expectations for Opthea Limited’s FY2029 Earnings (NASDAQ:OPT) - Defense World
Opthea Prepares for Phase 3 Results with Leadership Revamp - TipRanks
Finanzdaten der Opthea Limited Adr-Aktie (OPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):